Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats

Planta Medica

Volumn 77, Issue 16, 2011, Pages 1800-1805

  Lin, Shiuan Pey ^a   Tsai, Shang Yuan ^a   Lee Chao, Pei Dawn ^a   Chen, Ying Chen ^a   Hou, Yu Chi ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

HPLC; Magnolia officinalis; Magnoliaceae; magnolol; pharmacokinetics; sulfates glucuronides; tissue distribution

Indexed keywords

BETA GLUCURONIDASE; GLUCURONIDE; MAGNOLOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; KIDNEY; LIVER; LUNG; MAGNOLIACEAE; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUGS, CHINESE HERBAL; INJECTIONS, INTRAVENOUS; LIGNANS; MAGNOLIA; MALE; MEDICINE, CHINESE TRADITIONAL; PLANT BARK; PLANTS, MEDICINAL; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TAIWAN; TIME FACTORS; TISSUE DISTRIBUTION;

MAGNOLIA OFFICINALIS; MAGNOLIACEAE; RATTUS;

EID: 80755190007     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1271159     Document Type: Article

References (33)

1. Chen Q S. Houpo. In: Chang H M. But P P. H. editors Pharmacology and applications of Chinese materia medica. Singapore World Scientific 1986 878-880
2. Wang J P., Hsu M F., Raung S L., Chang L C., Tsao L T., Lin P L., Chen C C. Inhibition by magnolol of formylmethionyl-leucyl-phenyl alanine-induced respiratory burst in rat neutrophils. J Pharm Pharmacol 1999 51 285-294 (Pubitemid 29192782)
3. Lin Y R., Chen H H., Ko C H., Chan M H. Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 2007 81 1071-1078
4. Lee J, Jung E, Park J, Jung K, Lee S, Hong S, Park J, Park E, Kim J, Park S, Park D. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med 2005 71 338-343 (Pubitemid 40676458)
5. Park J, Lee J, Jung E, Park Y, Kim K, Park B, Jung K, Park E, Kim J, Park D. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 2004 496 189-195 (Pubitemid 39024332)
6. Lin S Y., Chang Y T., Liu J D., Yu C H., Ho Y S., Lee Y H., Lee W S. Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Mol Carcinogen 2001 32 73-83
7. Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med 2001 67 705-708 (Pubitemid 33044474)
8. Lin S Y., Liu J D., Chang H C., Yeh S D., Lin C H., Lee W S. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 2002 84 532-544
9. Ikeda K, Nagase H. Magnolol has the ability to induce apoptosis in tumor cells. Biol Pharm Bull 2002 25 1546-1549 (Pubitemid 39663667)
10. Chang B, Lee Y, Ku Y, Bae K, Chung C. Antimicrobial activity of magnolol and honokiol against periodontopathic microorganisms. Planta Med 1998 64 367-369 (Pubitemid 28234278)
11. Ho K Y., Tsai C C., Chen C P., Huang J S., Lin C C. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res 2001 15 139-141
12. Chan S S., Zhao M, Lao L, Fong H H., Che C T. Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated guinea pig ileum. Planta Med 2008 74 381-384 (Pubitemid 351578793)
13. Nakazawa T, Yasuda T, Ohsawa K. Metabolites of orally administered Magnolia officinalis extract in rats and man and its antidepressant-like effects in mice. J Pharm Pharmacol 2003 55 1583-1591 (Pubitemid 37441366)
14. Watanabe K, Watanabe H, Goto Y, Yamaguchi M, Yamamoto N, Hagino K. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects. Planta Med 1983 49 103-108 (Pubitemid 14239052)
15. D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 2007 43 348-361
16. 14C]magnolol in rats. Chem Pharm Bull (Tokyo) 1986 34 158-167 (Pubitemid 16135903)
17. Tsai T H., Chou C J., Chen C F. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J Pharm Pharmacol 1996 48 57-59 (Pubitemid 26128686)
18. Shipkova M, Wieland E. Glucuronidation in therapeutic drug monitoring. Clin Chim Acta 2005 358 2-23 (Pubitemid 40966628)
19. Ritter J K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 2000 129 171-193 (Pubitemid 32061059)
20. Kauffman F C. Sulfonation in pharmacology and toxicology. Drug Metab Rev 2004 36 823-843 (Pubitemid 39453076)
21. Kaminsky L S., Zhang Q Y. The small intestine as a xenobiotic- metabolizing organ. Drug Metab Dispos 2003 31 1520-1525 (Pubitemid 37466920)
22. Rice-Evans C, Spencer J P., Schroeter H, Rechner A R. Bioavailability of flavonoids and potential bioactive forms in vivo. Drug Metabol Drug Interact 2000 17 291-310 (Pubitemid 32047539)
23. Liu Z, Hu M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 2007 3 389-406 (Pubitemid 47316031)
24. Tsai T H., Chou C J., Lee T F., Wang L C. H., Chen C H. Pharmacokinetic and pharmacodynamic studies of magnolol after oral administration in rats. Pharm Sci 1996 2 191-193 (Pubitemid 28121805)
25. Sperker B, Murdter T E., Schick M, Eckhardt K, Bosslet K, Kroemer H K. Interindividual variability in expression and activity of human -glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther 1997 281 914-920 (Pubitemid 27203827)
26. Hanson S R., Best M D., Wong C H. Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed Engl 2004 43 5736-5763
27. Coughtrie M W., Sharp S, Maxwell K, Innes N P. Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. Chem Biol Interact 1998 109 3-27 (Pubitemid 28161098)
28. Wittwer E, Kern S E. Role of morphine's metabolites in analgesia: concepts and controversies. AAPS J 2006 8 E348-E352 (Pubitemid 43840593)
29. Joshi G P. Morphine-6-glucuronide, an active morphine metabolite for the potential treatment of post-operative pain. Curr Opin Investig Drugs 2008 9 786-799 (Pubitemid 351950874)
30. Yang J H., Hsia T C., Kuo H M., Chao P D., Chou C C., Wei Y H., Chung J G. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos 2006 34 296-304
31. Moon J H., Tsushida T, Nakahara K, Terao J. Identification of quercetin 3-O- -D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med 2001 30 1274-1285 (Pubitemid 32463938)
32. Fang S H., Hou Y C., Chang W C., Hsiu S L., Chao P D., Chiang B L. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 2003 74 743-756
33. Hsieh C L., Chao P D., Fang S H. Morin sulphates/glucuronides enhance macrophage function in microgravity culture system. Eur J Clin Invest 2005 35 591-596